Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo Nordisk B | Copenhagen | Healthcare | Pharmaceuticals | DKK 1.55T | 14.1x | 0.57 | DKK 348.10 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.6% Upside | Upgrade to Pro+ | |
| ALK-Abello B | Copenhagen | Healthcare | Pharmaceuticals | DKK 41.07B | 44.4x | 0.7 | DKK 186 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -3.8% Downside | Upgrade to Pro+ | |
| H Lundbeck B | Copenhagen | Healthcare | Pharmaceuticals | DKK 37.44B | 11.1x | 0.3 | DKK 38.60 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.6% Upside | Upgrade to Pro+ | |
| H Lundbeck AS | Copenhagen | Healthcare | Pharmaceuticals | DKK 37.44B | 11.1x | 0.3 | DKK 32.55 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Bavarian Nordic | Copenhagen | Healthcare | Pharmaceuticals | DKK 18.57B | 14.3x | 0.46 | DKK 236.90 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3% Upside | Upgrade to Pro+ | |
| Stenocare AS | Copenhagen | Healthcare | Pharmaceuticals | DKK 26.36M | -0.5x | 0.02 | DKK 0.70 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |